CJ-13,610

CJ-13,610 is a **novel orally active, nonredox-type inhibitor of 5-lipoxygenase (5-LOX)**, an enzyme crucial to the biosynthesis of leukotrienes from arachidonic acid, and thereby a key target in inflammatory pathways. It potently suppresses 5-LOX product formation, including leukotriene B4, in vitro and in vivo, acting competitively with arachidonic acid. CJ-13,610 was originally discovered by deCode Genetics and later developed by Pfizer for its anti-inflammatory properties, with primary indications in asthma, chronic obstructive pulmonary disease (COPD), and pain. Clinical trials included phase II studies for COPD and asthma, but these development efforts were eventually discontinued. It has also served as a model compound in studies of in vitro–in vivo correlation for 5-LO inhibitors[1][3][4][5][6][7].

Other names

tetrahydro-4-[3-[[4-(2-methyl-1H-imidazol-1-yl)phenyl]thio]phenyl]-2H-pyran-4-carboxamide